Breaking News

Laureate Completes Drug Product for Trials

Laureate Pharma and Iconic Therapeutics, a developer of ophthalmic products, have completed the manufacture of the first GMP lot of hI-con1 recombinant Fc-Factor VII fusion protein for the potential treatment of macular degeneration and other diseases.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Laureate Pharma and Iconic Therapeutics, a developer of ophthalmic products, have completed the manufacture of the first GMP lot of hI-con1 recombinant Fc-Factor VII fusion protein for the potential treatment of macular degeneration and other diseases. “We are very excited that Iconic Therapeutics now has material to test this new therapy for patients with macular degeneration and other diseases,” said Robert J. Broeze, Ph.D., president and chief executive officer of Laureate Phar...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters